1.83
3.17%
-0.06
アフターアワーズ:
1.82
-0.01
-0.55%
Protara Therapeutics Inc (TARA) 最新ニュース
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - Yahoo Finance
Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com
Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada
Protara reveals high choline deficiency in PS patients - Investing.com India
Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire
Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Protara reveals high choline deficiency in PS patients - Investing.com
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily
Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex
A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News
Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart
Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily
Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com
TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World
Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World
Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World
HC Wainwright Reaffirms Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? - Simply Wall St
Protara Therapeutics price target lowered to $20 from $22 at Guggenheim - TipRanks
Protara Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Head to Head Review: Protara Therapeutics (NASDAQ:TARA) and Gilead Sciences (NASDAQ:GILD) - Defense World
TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - MSN
Protara Therapeutics: Q2 Earnings Snapshot - mySA
TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Protara Therapeutics: Q2 Earnings Snapshot - Darien Times
Protara Therapeutics: Q2 Earnings Snapshot - The Advocate
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Head to Head Survey: Protara Therapeutics (NASDAQ:TARA) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
Oppenheimer & Co. Inc. Takes $40,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - American Banking and Market News
Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 11,396 Shares of Stock - Defense World
Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com India
Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com
Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com UK
Protara Therapeutics Inc (TARA) Becoming More Attractive for Investors - Knox Daily
Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 8,497 Shares of Stock - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 47,993 Shares - American Banking and Market News
Opaleye management sells shares worth $175,841 in Protara Therapeutics - Investing.com India
Opaleye management sells shares worth $175,841 in Protara Therapeutics - Investing.com
Autodesk COO Steven Blum sells $4.92 million in company stock - Investing.com
Opaleye management sells shares worth $175,841 in Protara Therapeutics By Investing.com - Investing.com India
Opaleye management sells shares worth $175,841 in Protara Therapeutics By Investing.com - Investing.com UK
Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors - Yahoo Finance UK
大文字化:
|
ボリューム (24 時間):